Summary & Overview
HCPCS J0879: Injection of difelikefalin for ESRD on Dialysis
HCPCS Level II code J0879 identifies an injection of difelikefalin, 0.1 microgram, for patients with end-stage renal disease receiving dialysis. This code captures administration of a specialty injectable therapy used within the dialysis setting and is relevant to outpatient dialysis centers and hospital outpatient infusion units. Nationally, accurate capture of J0879 affects specialty drug coverage, dialysis bundle accounting, and Medicare and commercial payer reimbursement workflows.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and coding context for this dialysis-specific injectable, typical sites of service, and the payer landscape that typically covers infusion and injectable therapies in the ESRD population. The publication provides benchmarks and policy-oriented updates relevant to billing practices and reimbursement classification for specialty injectables in dialysis, alongside clinical context needed for correct service-line attribution.
The content is aimed at revenue cycle, dialysis clinic administrators, and policy analysts seeking clear, national-level guidance on how this HCPCS Level II code is used and what to expect from major payers in coverage and claims processing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0879 represents an injection of difelikefalin, dosed at 0.1 microgram, specifically indicated for end-stage renal disease (ESRD) patients on dialysis. This service is a pharmacologic infusion/injectable therapy administered to manage clinical symptoms in the dialysis population.
Service type: Injectable drug administration (renal dialysis population)
Typical site of service: Outpatient dialysis center or hospital outpatient infusion center, reflecting administration during or in conjunction with maintenance dialysis sessions.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with end-stage renal disease (ESRD) receiving maintenance hemodialysis who experiences moderate-to-severe chronic pruritus refractory to topical measures and antihistamines. The patient presents to an outpatient dialysis unit on a scheduled dialysis day. The dialysis nurse or dialysis clinic clinician documents persistent itching despite prior conservative treatments and confirms indication for intravenous administration of difelikefalin during the dialysis session. Medication is prepared per facility medication policies, labeled as J0879 (difelikefalin, 0.1 microgram units), and administered intravenously via the dialysis venous access at the prescribed dose and timing relative to the dialysis treatment. Vital signs and any immediate adverse reactions are monitored during and after the injection. Documentation includes the indication (pruritus due to ESRD), dose administered, route, date/time, lot number, and related dialysis session details. Billing is submitted using HCPCS Level II code J0879 with applicable modifier(s) to reflect circumstances such as professional/technical circumstances, partial administration, or supplier billing nuances. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for ESRD dialysis-associated therapy coverage decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |